Whereas inflammation within the pancreatic cancer microenvironment, seemingly due to NF-κB activation, has been linked to tumor progression and chemoresistance, these findings reinforce preclinical evidence that the complementary therapy to other chemotherapeutic agents with CUR exhibits beneficial efficacy and safety during anticancer therapy. The gene discussed is NFKB1; the disease is pancreatic neoplasm.